BIOX vs FCX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health scores paint a dire picture: BIOX has a Piotroski F-Score of just 2/9, indicating severe financial weakness. Despite low valuation multiples like a Price/Book of 0.29 and Price/Sales of 0.24, the company is unprofitable with a -17.72% profit margin and deteriorating fundamentals, including -16.40% YoY revenue growth and a -300% YoY EPS decline. Earnings volatility is extreme, with a history of massive negative surprises averaging -268.89% over the last four quarters, and the stock has lost over 85% of its value in five years. While the Forward P/E of 1.88 may appear attractive, it is unsupported by cash flow, balance sheet clarity, or consistent earnings, and the lack of an Altman Z-Score due to missing data further elevates risk.
FCX shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
BIOX vs FCX: Head-to-Head Comparison
This page compares Bioceres Crop Solutions Corp. (BIOX) and Freeport-McMoRan Inc. (FCX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.